Role of Ivabradine in reducing tachycardia induced adverse outcomes in severe septic shock

Not Applicable

Conditions: Health Condition 1: O- Medical and Surgical

Registration Number: CTRI/2022/01/039557

Lead Sponsor: Calcutta national medical college

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1. In age of 18 to 50 years,

2. Patients who are admitted in intensive care units (both medical and surgical) and received intensive care management for ongoing and properly diagnosed septic shock, following any condition.

3. Patients who obeyed the haemodynamic, haematological, cardiovascular, renal and other valued parameters used in diagnosing sepsis.

4. Patients who showed active bacterial growth in blood culture and sensitivity

5. Patients who had a significantly raised heart rate above 100/min

Exclusion Criteria

1. Patients or their relatives refusing to give consent

2. Patients who have a documented cardiac ailment from echocardiography findings. (ie. cardiac failure, previous infarction)

3. Patients with Chronic kidney disease, DCLD

4. Patients with documented neurologic disorder prior to sepsis

5. Paediatric patients, Age <18 yrs.

6. Patient requiring more than two vasopressors at a time for maintaining haemodynamics.

7. Patients who had associated ARDS at the time of vasopressor initiation and requiring high PEEP.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serial analysis of BP and HR were monitored for every patient. BP and HR recording every 15 minutes interval, finally a mean over every six hours is taken for calculation. A 15 day monitored values were finally taken into consideration for the study.Timepoint: 6 hourly assessment of the afore mentioned outcome parameters over a period of 15 days

Secondary Outcome Measures

Name	Time	Method
The secondary outcome variables include severity of adverse events like nausea vomiting, degree of sedation, hemodynamic variables and average duration of hospital stay. <br/ ><br>Routine blood analysis will be also done throughout the study period to ensure no adverse events during the treatment are present.Timepoint: continuous monitoring for a period of 15 days